China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

 
• By Dexter Jie Yan
  
define
China's public payer is attempting to define innovation in drug development while capping innovative drug prices. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from China

More from Asia